| Half-life | 2 hours |
| Tmax | 1.5 h |
| Bioavailability | 50 % (approx) |
| Protein Binding | 95 % |
| Volume of Distribution | 0.2 L/kg (approx) |
| Clearance Route | renal |
| Active Metabolites | no |
| Notes | Rapid onset (30–60 min orally); excreted largely unchanged in urine; efficacy maintained in low GFR; may cause electrolyte depletion. |
Severity: Severe
Adverse Effects:
Dehydration, hypokalemia, metabolic alkalosis, ototoxicity, hypotension
Contraindications:
Anuria, severe electrolyte imbalance
Precautions:
Monitor electrolytes, renal function, and hearing in high-dose IV use; caution in elderly and hepatic disease